Prevention and Early Detection Biomarkers of Adenomas and CRC Lesions During CRC Screening
NCT ID: NCT02596113
Last Updated: 2019-03-13
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
92 participants
Study Classification
OBSERVATIONAL
Study Start Date
2015-07-31
Study Completion Date
2018-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators designed a prospective study to evaluate the predictive ability of detection of mutations in genes involved in carcinogenesis of the colon (eg hMLH1, K-Ras, B-Raf, ccfDNA) in a sample of Greek population presents for conducting colonoscopy in the context of screening under international CRC prevention instructions. This investigation will be carried out in individuals in normal risk in order to study specific mutations (in blood and tissue) to draw reliable conclusions about whether we can detect (with greater sensitivity and specificity) patients with precancerous lesions or CRC with a simple blood test thereby reducing the cost and side effects of repeated endoscopic procedures.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Molecular Profiling of Colorectal Cancer
NCT04863768
Colorectal Cancer
Colon Cancer
Colon Adenocarcinoma
UNKNOWN
Identification of New Non-invasive, Predictive, and Diagnostic Biomarkers for Colorectal Cancer
NCT07153458
CRC (Colorectal Cancer)
Adenoma Colon
RECRUITING
Peripheral Blood DNA Methylation Markers for the Early Detection of Colorectal Carcinoma in the Egyptian Population
NCT01793207
Colorectal Neoplasms
Adenoma
Colorectal Tumors
COMPLETED
Innovative Approach to Detect Recurrent Colorectal Lesions With Surveillance Via Mutation Analysis & Clinical Phenotype
NCT05929365
Predictive Cancer Model
RECRUITING
To Investigate Risk of Colorectal Neoplasms in First-degree Relatives of Patients With Non-advanced Adenomas
NCT02521727
Colorectal Cancer
Colorectal Adenoma
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Colorectal cancer (CRC) is the third most frequent cancer worldwide with a prevalence of 1.5 million people / year and is the second cause of death from cancer (650 000 deaths per year) for both genders after lung cancer.
In Greece it is estimated that about 3000 people are infected annually by the CRC. Risk factors for the emergence of CRC are: old age, positive family history of cancer and colon polyps, diet poor in fiber and rich in high-calorie fats and foods, sedentary lifestyle and lack of exercise from everyday life. Additionally, obesity, smoking, alcohol consumption in large quantities, diabetes, inflammatory conditions of the intestine such as ulcerative colitis and Crohn's Crohn, and some inherited disorders affecting colon are factors that increase the risk for the CRC.
It is a silent and insidious disease since most patients do not present symptoms in the early stages (such as bleeding, abdominal pain), resulting in diagnosis in a non-curable phase. This makes it clear that survival depends on the stage of disease at time of diagnosis. For example a patient with cancer Dukes' stage A, 5-year survival is about 93% whereas stage C, is about 47%. Based on the above it is clear that early detection of precancerous colorectal lesions is the cornerstone for the optimal treatment of this disease.
The CRC is an ideally disease to implement mass screening in general population as it follows a specific development process that lasts 7-12 years, leading to transformation of normal epithelium to adenoma and eventually carcinoma.
There are multiple options available for CRC detection involving the detection of blood in fecal test (or microscopic examination of fecal hemoglobin), the flexible sigmoidoscopy and colonoscopy. Each of these has advantages and disadvantages. Specifically, the microscopic examination of fecal hemoglobin although reduces mortality by 16% by CRC nevertheless exhibits low sensitivity to detect polyps and cancerous lesions in the distal colon and small specificity thus be, in economic terms, negative test to be used in mass screening. Regarding the flexible sigmoidoscopy, this is a test clearly faster and safer than colonoscopy but with small percentage of patient compliance, efficacy clear depended on the quality of bowel preparation and most importantly, it can not see the whole intestine. Computed tomographic colonography is another method of finding new precancerous lesions but because of the short diagnostic accuracy compared to the colonoscopy and radiation, is not recommended for mass screening.
A colonoscopy is the best method for the diagnosis of polyps and CRC to date, and also prevents the CRC by detecting adenomatous polyps and through polypectomy. It allows the inspection of the entire lumen of the colon resulting in both distal and proximal lesions to be discovered. He has the greatest sensitivity by all methods in the detection of the CRC. The disadvantages of this method is the cost, bowel perforation and bleeding risks (especially after polypectomy), the difficulty in the preparation of patients using laxatives liquid, the need for sedation during the procedure, low levels of compliance and patient intolerance .
It becomes necessary to identify simpler, less invasive and more affordable methods of finding precancerous lesions for sporadic type of CRC. One such method is the use of potential biomarkers (i.e. objectively measurable indicators of a normal or abnormal process) using a sample of blood (plasma) of the person in order to find mutations or epigenetic changes in known genes that have been implicated to participate in the process of carcinogenesis of CRC.
More specific, there are at least three main paths that lead to carcinogenesis of colorectal lesions: the way of chromosomal instability (CIN), the path of microsatellite instability (MSI) and finally the path of methylated phenotype of the islands of cytosine-phosphate-guanine (CpG island) known as CpG Island Methylation Pathway (CIMP). After long-term studies, it has been found that in every path there is a participation of genes through their mutations and/or their epigenetic changes.
For example the path of chromosomal abnormality gathers the point mutations of some oncogenes and tumor suppressing genes such as APC, KRAS, BRAF, SMAD 4, and TP53.
The route of microsatellite instability, which is a result of the malfunctioning of the DNA repair genes (DNA mismatch repair genes -MMR), leads to multiple mutations and it is the cause of 15% of sporadic type of CRC by an abnormal epigenetic methylation of the MLH1gene. Eventually, the third path, CIMP, consists of two subtypes: the first is associated with mutations in the BRAF gene, known as CIMP-High, and the second associated with mutations in the KRAS gene, known as, CIMP-Low.
Additionally, the presence of circulating nucleic acids (circulating cell-free DNA) in the blood circulation in cancer patients has led to the belief that these nucleic acids derived from cancerous cells and therefore may be used in the early detection of precancerous or cancerous colorectal lesions.
Therefore it is becoming increasingly strong need to find new biomarkers that will lead us with lower costs and safety, closer to precancerous colon lesions, treating one of the most important health problems of our century.
Based on the above, we designed a prospective study to evaluate the predictive ability of detection of mutations in genes involved in carcinogenesis of the colon (eg hMLH1, K-Ras, B-Raf, ccfDNA) in a sample of Greek population presents for conducting colonoscopy in the context of screening under international CRC prevention instructions. This investigation will be carried out in individuals in normal risk in order to study specific mutations (in blood and tissue) to draw reliable conclusions about whether we can detect (with greater sensitivity and specificity) patients with precancerous lesions or CRC with a simple blood test thereby reducing the cost and side effects of repeated endoscopic procedures.
The sample to be studied will consist of approximately 90-100 individuals in normal risk for developing CRC aged 50-75 years, will undergo preventive colonoscopy for polyps and CRC detection. Participants will be divided into three groups of patients according to the findings during endoscopy: those without pathological findings, those with polyps between 1 to 3 centimeters diameter and adenomatous elements in pathology examination and finally those with colorectal cancer. From all these three populations, samples would be collected from peripheral blood (plasma) and colon tissue biopsy (normal or abnormal, respectively) in order to find a possible common mutations of some genes involved in the pathogenesis of the CRC in these 3 groups \[e.g. in KRAS12, 13, 61, BRAF (V600E), ccfDNA some point mutations in hMLH1\]. The samples of blood and tissue will be placed in a blood bottle with a specific anticoagulant and preservative (RNA latter) and subsequently stored at -20 degrees for maintenance. The genome analysis of potential mutations will be done by specific commercial DNA kit and specific PCR techniques. Then according to the results, it will be carried out a try to present statistically significant elements compatible or not with the original purpose of the investigation.
The effectiveness of the screening program depends on the accuracy and acceptability of the method used for detecting a pathological condition. An ideal screening test should have high compliance, high sensitivity and specificity, to be minimally invasive and cost-efficient. Because of the limitations of existing colon cancer screening methods there is a growing need to find new diagnostic methods for precancerous lesions and one of them are the molecular biomarkers that will be valuable tools in our arsenal to a safer approach to healthy subjects who are at high risk for CRC.
In Greece it is estimated that about 3000 people are infected annually by the CRC. Risk factors for the emergence of CRC are: old age, positive family history of cancer and colon polyps, diet poor in fiber and rich in high-calorie fats and foods, sedentary lifestyle and lack of exercise from everyday life. Additionally, obesity, smoking, alcohol consumption in large quantities, diabetes, inflammatory conditions of the intestine such as ulcerative colitis and Crohn's Crohn, and some inherited disorders affecting colon are factors that increase the risk for the CRC.
It is a silent and insidious disease since most patients do not present symptoms in the early stages (such as bleeding, abdominal pain), resulting in diagnosis in a non-curable phase. This makes it clear that survival depends on the stage of disease at time of diagnosis. For example a patient with cancer Dukes' stage A, 5-year survival is about 93% whereas stage C, is about 47%. Based on the above it is clear that early detection of precancerous colorectal lesions is the cornerstone for the optimal treatment of this disease.
The CRC is an ideally disease to implement mass screening in general population as it follows a specific development process that lasts 7-12 years, leading to transformation of normal epithelium to adenoma and eventually carcinoma.
There are multiple options available for CRC detection involving the detection of blood in fecal test (or microscopic examination of fecal hemoglobin), the flexible sigmoidoscopy and colonoscopy. Each of these has advantages and disadvantages. Specifically, the microscopic examination of fecal hemoglobin although reduces mortality by 16% by CRC nevertheless exhibits low sensitivity to detect polyps and cancerous lesions in the distal colon and small specificity thus be, in economic terms, negative test to be used in mass screening. Regarding the flexible sigmoidoscopy, this is a test clearly faster and safer than colonoscopy but with small percentage of patient compliance, efficacy clear depended on the quality of bowel preparation and most importantly, it can not see the whole intestine. Computed tomographic colonography is another method of finding new precancerous lesions but because of the short diagnostic accuracy compared to the colonoscopy and radiation, is not recommended for mass screening.
A colonoscopy is the best method for the diagnosis of polyps and CRC to date, and also prevents the CRC by detecting adenomatous polyps and through polypectomy. It allows the inspection of the entire lumen of the colon resulting in both distal and proximal lesions to be discovered. He has the greatest sensitivity by all methods in the detection of the CRC. The disadvantages of this method is the cost, bowel perforation and bleeding risks (especially after polypectomy), the difficulty in the preparation of patients using laxatives liquid, the need for sedation during the procedure, low levels of compliance and patient intolerance .
It becomes necessary to identify simpler, less invasive and more affordable methods of finding precancerous lesions for sporadic type of CRC. One such method is the use of potential biomarkers (i.e. objectively measurable indicators of a normal or abnormal process) using a sample of blood (plasma) of the person in order to find mutations or epigenetic changes in known genes that have been implicated to participate in the process of carcinogenesis of CRC.
More specific, there are at least three main paths that lead to carcinogenesis of colorectal lesions: the way of chromosomal instability (CIN), the path of microsatellite instability (MSI) and finally the path of methylated phenotype of the islands of cytosine-phosphate-guanine (CpG island) known as CpG Island Methylation Pathway (CIMP). After long-term studies, it has been found that in every path there is a participation of genes through their mutations and/or their epigenetic changes.
For example the path of chromosomal abnormality gathers the point mutations of some oncogenes and tumor suppressing genes such as APC, KRAS, BRAF, SMAD 4, and TP53.
The route of microsatellite instability, which is a result of the malfunctioning of the DNA repair genes (DNA mismatch repair genes -MMR), leads to multiple mutations and it is the cause of 15% of sporadic type of CRC by an abnormal epigenetic methylation of the MLH1gene. Eventually, the third path, CIMP, consists of two subtypes: the first is associated with mutations in the BRAF gene, known as CIMP-High, and the second associated with mutations in the KRAS gene, known as, CIMP-Low.
Additionally, the presence of circulating nucleic acids (circulating cell-free DNA) in the blood circulation in cancer patients has led to the belief that these nucleic acids derived from cancerous cells and therefore may be used in the early detection of precancerous or cancerous colorectal lesions.
Therefore it is becoming increasingly strong need to find new biomarkers that will lead us with lower costs and safety, closer to precancerous colon lesions, treating one of the most important health problems of our century.
Based on the above, we designed a prospective study to evaluate the predictive ability of detection of mutations in genes involved in carcinogenesis of the colon (eg hMLH1, K-Ras, B-Raf, ccfDNA) in a sample of Greek population presents for conducting colonoscopy in the context of screening under international CRC prevention instructions. This investigation will be carried out in individuals in normal risk in order to study specific mutations (in blood and tissue) to draw reliable conclusions about whether we can detect (with greater sensitivity and specificity) patients with precancerous lesions or CRC with a simple blood test thereby reducing the cost and side effects of repeated endoscopic procedures.
The sample to be studied will consist of approximately 90-100 individuals in normal risk for developing CRC aged 50-75 years, will undergo preventive colonoscopy for polyps and CRC detection. Participants will be divided into three groups of patients according to the findings during endoscopy: those without pathological findings, those with polyps between 1 to 3 centimeters diameter and adenomatous elements in pathology examination and finally those with colorectal cancer. From all these three populations, samples would be collected from peripheral blood (plasma) and colon tissue biopsy (normal or abnormal, respectively) in order to find a possible common mutations of some genes involved in the pathogenesis of the CRC in these 3 groups \[e.g. in KRAS12, 13, 61, BRAF (V600E), ccfDNA some point mutations in hMLH1\]. The samples of blood and tissue will be placed in a blood bottle with a specific anticoagulant and preservative (RNA latter) and subsequently stored at -20 degrees for maintenance. The genome analysis of potential mutations will be done by specific commercial DNA kit and specific PCR techniques. Then according to the results, it will be carried out a try to present statistically significant elements compatible or not with the original purpose of the investigation.
The effectiveness of the screening program depends on the accuracy and acceptability of the method used for detecting a pathological condition. An ideal screening test should have high compliance, high sensitivity and specificity, to be minimally invasive and cost-efficient. Because of the limitations of existing colon cancer screening methods there is a growing need to find new diagnostic methods for precancerous lesions and one of them are the molecular biomarkers that will be valuable tools in our arsenal to a safer approach to healthy subjects who are at high risk for CRC.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Colorectal Cancer
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
CASE_CONTROL
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
No pathological findings
blood and biopsy samples from normal colon mucosa
No interventions assigned to this group
>1 cm adenomatous polys
blood and biopsy samples from the polyp
No interventions assigned to this group
Colorectal cancer
blood (plasma) and biopsy samples from colorectal cancer
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* normal risk for developing CRC aged 50-75 years who undergo preventive colonoscopy for polyps and CRC detection
Exclusion Criteria
\-
Minimum Eligible Age
50 Years
Maximum Eligible Age
75 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National and Kapodistrian University of Athens
OTHER
Sponsor Role
collaborator
Evangelismos Hospital
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nikos Viazis
Director Gastroenterology
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nikos Viazis, Director
Role: PRINCIPAL_INVESTIGATOR
Evangelismos Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Evangelismos Hospital
Athens, Attica, Greece
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Greece
References
Explore related publications, articles, or registry entries linked to this study.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010 Dec 15;127(12):2893-917. doi: 10.1002/ijc.25516.
Reference Type
RESULT
Pox CP, Altenhofen L, Brenner H, Theilmeier A, Von Stillfried D, Schmiegel W. Efficacy of a nationwide screening colonoscopy program for colorectal cancer. Gastroenterology. 2012 Jun;142(7):1460-7.e2. doi: 10.1053/j.gastro.2012.03.022. Epub 2012 Mar 21.
Reference Type
RESULT
Deschoolmeester V, Baay M, Specenier P, Lardon F, Vermorken JB. A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist. 2010;15(7):699-731. doi: 10.1634/theoncologist.2010-0025. Epub 2010 Jun 28.
Reference Type
RESULT
Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology. 2010 Jun;138(6):2059-72. doi: 10.1053/j.gastro.2009.12.065.
Reference Type
RESULT
Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010 Jun;138(6):2073-2087.e3. doi: 10.1053/j.gastro.2009.12.064.
Reference Type
RESULT
Schee K, Fodstad O, Flatmark K. MicroRNAs as biomarkers in colorectal cancer. Am J Pathol. 2010 Oct;177(4):1592-9. doi: 10.2353/ajpath.2010.100024. Epub 2010 Sep 9.
Reference Type
RESULT
Shen L, Toyota M, Kondo Y, Lin E, Zhang L, Guo Y, Hernandez NS, Chen X, Ahmed S, Konishi K, Hamilton SR, Issa JP. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18654-9. doi: 10.1073/pnas.0704652104. Epub 2007 Nov 14.
Reference Type
RESULT
Soreide K, Janssen EA, Soiland H, Korner H, Baak JP. Microsatellite instability in colorectal cancer. Br J Surg. 2006 Apr;93(4):395-406. doi: 10.1002/bjs.5328.
Reference Type
RESULT
Baylin SB, Hoppener JW, de Bustros A, Steenbergh PH, Lips CJ, Nelkin BD. DNA methylation patterns of the calcitonin gene in human lung cancers and lymphomas. Cancer Res. 1986 Jun;46(6):2917-22.
Reference Type
RESULT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
galanopoulosm
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
NCT05234177
RECRUITING
Microbiome Testing for the Screening of Colorectal Cancer
NCT06588166
RECRUITING
Exploratory Study of a Novel Based rbcDNA Liquid Biopsy Technique for Colorectal Cancer Early Detection
NCT05875584
COMPLETED
Personalized Screening Plans to Increase Colorectal Cancer Screening in Healthy Participants
NCT00617071
UNKNOWN
PHASE3
Diagnostic and Prognosis Value of Circulating DNA for CRC Patients' Surveillance After Curative Treatment
NCT02813928
COMPLETED
NA
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies
NCT01260168
COMPLETED
A Program for Improved Family Screening for Colorectal Cancer
NCT03620877
UNKNOWN
NA
Early-Onset Colorectal Cancer Recurrence
NCT06271980
COMPLETED
New bioMarkers tO straTIfy cOlorectal caNcer Referrals
NCT07035691
RECRUITING
Validation of Colon Biomarkers for the Early Detection of Colorectal Adenocarcinoma
NCT01511653
COMPLETED
Characterization of Brazilian Colorectal Cancer Screening Population
NCT03355391
UNKNOWN
Colorectal Cancer Screening Intervention for Family Members of Colorectal Cancer Patients
NCT00582829
COMPLETED
CRC Screening in Unscreened Individuals 45-54
NCT06757192
RECRUITING
Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas
NCT00843375
RECRUITING
Evaluation of Some Risk Factors Associated With Colorectal Cancer
NCT05170360
UNKNOWN
Endomicrocancer: Confocal Endomicroscopy in Patients With High Risk of Colorectal Cancer
NCT01052376
TERMINATED
NA
The Future Management of Patients With Neoplasms of the Gastro-intestinal Tract
NCT06728358
ACTIVE_NOT_RECRUITING
NA
Predicting Disease Progression and/or Recurrence in Cancer
NCT04776837
COMPLETED
Case Volume and Adenoma Rate During Screening Colonoscopy
NCT00860665
COMPLETED
Polyprev: Study to Compare Fecal Immunochemical Test With Endoscopic Surveillance After Advanced Adenoma Resection in Fecal Immunochemical Test Colorectal Cancer Screening Programs.
NCT04967183
RECRUITING
NA
Screening for CRC Using a Mixed Strategy of Sigmoidoscopy and Colonoscopy in Average-Risk Population According to Age
NCT00173277
UNKNOWN
CARE-CRC: Microbiome Insights and Correlations for Risk and Outcomes in Colorectal Cancer
NCT06734156
NOT_YET_RECRUITING
Risk of Metachronous Advanced Colorectal Neoplastic Among Individuals With Varying Numbers of Non-Advanced Adenomas Detected During Screening Colonoscopy
NCT07302139
COMPLETED
Multicentre Study for Data Collection, Development, and Evaluation of Novel CRC Screening and Diagnostic Methods
NCT06515821
RECRUITING
Intraoperative Flow Cytometry In Colorectal Cancer
NCT05261542
COMPLETED